THRM closed at $29.91 on April 28. The stock is up 3.5% on the week and 8% over the past month. That recovery follows a Q1 earnings beat — and the real story this week is in what happened to the options market immediately after the print.
The options picture is striking. For most of the past month, the put/call ratio had been running in the 4.5 range — an unusually heavy skew toward put protection relative to calls. Then on April 28, it collapsed to 0.50. That is more than four standard deviations below the 20-day mean of 4.32, flipping the market from heavily defensive to the most call-dominant posture of the past year in a single session. The trigger was the Q1 earnings release on April 23, which saw the stock gain roughly 6% on the day. Post-print, traders rotated out of their hedges and into calls — a clean sentiment reset after the uncertainty cleared.
Short positioning reinforces that read. Shorts have been paring back steadily: SI % of free float now runs at about 2.0%, down from roughly 2.2% a month ago. Over the past week alone, estimated short shares fell by more than 6%. Borrow costs remain inconsequentially low at 0.72% annualised, and availability in the lending market is extremely loose — there is no sign of squeeze dynamics or meaningful conviction from the bear side. The ORTEX short score drifted lower through April, from 32.3 on April 17 to 31.2 by April 28, tracking the gradual short-side retreat.
The Street reflects a constructive but selective view. Five analysts carry buy ratings versus three holds. The consensus price target is around $40, implying roughly 34% upside from current levels — a gap that the analyst-recommendation-divergence factor score, running in the 92nd percentile, flags as unusually wide relative to peers. Stifel maintained its Buy rating and lifted its target to $38 on April 24, immediately after the Q1 results. Baird kept its Neutral but also bumped its target modestly, to $34. JPMorgan moved the other direction, cutting its target from $42 to $37 while holding Neutral — a signal that the tariff and auto-demand backdrop still keeps some on the sidelines despite the solid quarter. Valuation remains undemanding: the EV/EBITDA multiple is running near 5.3x, and the trailing P/E of roughly 10.7x prices in very little recovery optionality on the auto cycle. On consensus forward estimates, revenue runs near $1.56 billion and normalised net income near $83 million.
Institutional ownership shows passive giants at the top and no dramatic recent activity. BlackRock holds about 15% of shares, Vanguard roughly 11%. American Century stands out as the most active recent buyer among the top holders, adding nearly 159,000 shares in the most recent quarter. Trigran Investments trimmed its stake by around 286,000 shares as of December 2025, but it remains a sizable holder at about 4.8% of shares. On the insider side, a cluster of executives — General Counsel, CTO, Chief Accounting Officer and several Senior VPs — sold small parcels in mid-March at prices in the $27–$29 range. The trades were modest in dollar terms (the largest was around $42,000) and carry significance scores of just 1 out of 10. At current prices of $29.91, the stock has already moved above those sale prices, suggesting the insider-sale activity carries limited signal.
Gentherm's next earnings event is scheduled for May 14. The past two prints produced positive 1-day moves — around 6% after April's Q1 release and nearly 4% after the February report — so the historical pattern has rewarded holders into results, though that streak is now a factor to watch as Q2 guidance commentary and auto-market tariff exposure move into focus for the next catalyst.
See the live data behind this article on ORTEX.
Open THRM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
